Abstract
Objective: Metastatic pancreatic cancer is a common condition and highly lethal condition, emphasizing the urgent need for
novel prognostic markers. This study investigated the effect of the gamma-glutamyl transferase/albumin ratio (GAR) and alkaline phosphatase/
albumin ratio (APAR) on prognosis. Material and Methods: We conducted a retrospective examination 287 patients diagnosed with
metastatic pancreatic cancer between January 2008 2019. Results: The median age was 65 years, and obstructive jaundice was present in 58
(20.2%). Median overall-surviva (OS) was significantly longer in patients without jaundice (6.0 vs. 3.0 months, p=0.005). Furthermore, median
OS and progression-free survival (PFS) were extended in the low-GAR-group (6.0 vs. 4.0 months, p=0.001; 5.0 vs. 3.0 months, p<0.01,
respectively). Similarly, patients in the low APAR group exhibited longer median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 3.0 months,
p<0.01, respectively). The low neutrophil-to-lymphocyte-ratio (NLR) group demonstrated prolonged median OS and PFS (8.0 vs. 3.0 months,
p<0.01; 6.0 vs. 3.0 months, p<0.01, respectively). Additionally, patients in the high prognostic-nutritional-index (PNI) group experienced extended
median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 2.0 months, p=0.02, respectively). Furthermore, members of the low-GARgroup
were significantly more prevalent in the low-NLR and low platelet-to-lymphocyte-ratio-groups (79.4% vs. 20.6%, p=0.02 and 75.9%
vs. 24.1%, p=0.04, respectively). By contrast, the low-APAR-group had significantly more members than the high-PNI-group (90% vs. 10%,
p<0.01). Conclusion: In metastatic pancreatic cancer, both OS and PFS significantly extend in the low-GAR, APAR, and NLR groups, while
the high-PNI-group also exhibits enhanced OS and PFS. These findings must be supported by further studies .
Keywords:
Metastatic pancreatic cancer, gamma-glutamyl transferase/albumin ratio, alkaline phosphatase/albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index
References
1Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
2Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
3Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006;(3):CD002093. Update in: Cochrane Database Syst Rev. 2009;(4):CD002093.
4Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265(1):185-191.
5Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52-60.
6van Geenen RC, van Gulik TM, Offerhaus GJ, et al. Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. Eur J Surg Oncol. 2001;27(6):549-557.
7Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17(7):1794-1801.
8van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362(2):129-137.
9Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
10Alagappan M, Pollom EL, von Eyben R, et al. Albumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRT. Am J Clin Oncol. 2018;41(3):242-247.
11Wu M, Guo J, Guo L, Zuo Q. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol. 2016;37(9):12525-12533.
12Yuce E, Alandag C, Cakir E, Fidan E. Prognostic factors in gastrointestinal stromal tumors (GIST): could prognostic nutritional index (PNI) be a new prognostic factor? J Coll Physicians Surg Pak. 2022;32(1):81-85.
13Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8(6):886-894.
14Li S, Xu H, Wu C, et al. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Med. 2019;8(2):572-584.
15Engelken FJ, Bettschart V, Rahman MQ, Parks RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol. 2003;29(4):368-373.
16Strasak AM, Goebel G, Concin H, et al; VHM&PP Study Group. Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancer. Cancer Res. 2010;70(9):3586-3593.
17Hofbauer SL, Stangl KI, de Martino M, et al. Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. Br J Cancer. 2014;111(8):1526-1531.
18Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of prostate cancer: Findings from the KIHD prospective cohort study. Int J Cancer. 2017;140(4):818-824.
19Pu N, Gao S, Xu Y, et al. Alkaline phosphatase-to-albumin ratio as a prognostic indicator in pancreatic ductal adenocarcinoma after curative resection. J Cancer. 2017 20;8(16):3362-3370.
20Carr BI, Guerra V. Hepatocellular carcinoma extrahepatic metastasis in relation to tumor size and alkaline phosphatase levels. Oncology. 2016;90(3):136-142.
21Ji F, Fu SJ, Guo ZY, et al. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2016;95(27):e4065.
22Shirai Y, Shiba H, Haruki K, et al. Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res. 2017;37(2):787-793.
23Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263-355.
24Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta. 2018;476:130-138.
25Neuman MG, Malnick S, Chertin L. Gamma glutamyl transferase - an underestimated marker for cardiovascular disease and the metabolic syndrome. J Pharm Pharm Sci. 2020;23(1):65-74.
26Li S, Wang A, Tian X, Zuo Y, Meng X, Zhang Y. Elevated gamma-glutamyl transferase levels are associated with stroke recurrence after acute ischemic stroke or transient ischemic attack. CNS Neurosci Ther. 2022;28(10):1637-1647.
27Strasak AM, Pfeiffer RM, Klenk J, et al; Vorarlberg Health Monitoring and Promotion Program Study Group. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. Int J Cancer. 2008;123(8):1902-1906.
28Strasak AM, Rapp K, Brant LJ, et al; VHM&PP Study Group. Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res. 2008;68(10):3970-3977.
29López-Posadas R, González R, Ballester I, et al. Tissue-nonspecific alkaline phosphatase is activated in enterocytes by oxidative stress via changes in glycosylation. Inflamm Bowel Dis. 2011;17(2):543-556.
30Dogan M, Algin E, Guven ZT, et al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer? Curr Med Res Opin. 2018;34(5):857-863.
